Search company, investor...

Metys Pharmaceuticals

Founded Year



Acquired | Acquired

Total Raised


About Metys Pharmaceuticals

Metys Pharmaceuticals is developing MP-101 to prevent and treat chemotherapy-induced peripheral neuropathy, an uncomfortable side effect of several important cancer treatments. On September 7th, 2021, Metys Pharmaceuticals was acquired by Novaremed. Terms of the transaction were not disclosed.

Headquarters Location

Gerbergasse 30

Basel, 4001,


+41 79 408 7982

Missing: Metys Pharmaceuticals's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Metys Pharmaceuticals's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Metys Pharmaceuticals

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Metys Pharmaceuticals is included in 1 Expert Collection, including Cancer.



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Metys Pharmaceuticals Patents

Metys Pharmaceuticals has filed 4 patents.

The 3 most popular patent topics include:

  • Neurological disorders
  • Piperidines
  • Rare diseases
patents chart

Application Date

Grant Date


Related Topics




Psychiatric diagnosis, Neurological disorders, Analgesics, Amines, Piperidines


Application Date


Grant Date



Related Topics

Psychiatric diagnosis, Neurological disorders, Analgesics, Amines, Piperidines



Latest Metys Pharmaceuticals News

Novaremed acquires Basel-based Metys Pharmaceuticals

Sep 14, 2021

Success 14.09.2021 The acquisition of Metys broadens Novaremed’s pipeline focused on novel, non-opioid development candidates for chronic pain indications with the addition of two complementary development projects. Among them is the patented Phase 2 clinical candidate MP-101. Novaremed , a privately-held clinical-stage biopharmaceutical company, announces the acquisition of Metys Pharmaceuticals AG (Metys), including all of its development programs, in an all-share transaction. The acquisition broadens Novaremed’s existing pipeline by adding both clinical and preclinical development projects based on an innovative approach for non-opioid chronic pain treatment, the company’s focus area. From now on, Novaremed’s pipeline to address neuropathic pain will focus on three non-opioid development projects with entirely different modes of action. The company’s candidate NDR NRD.E1, an orally active small molecule with a novel mechanism of action and patent protection until 2040. It acts as a Lyn kinase modulator and is the lead compound being developed to treat painful diabetic peripheral neuropathy (PDPN), affecting 1 in five diabetic patients. With positive results from Phase 2a dose-finding proof-of-concept study, an FDA Fast Track Designation and IND-approval Novaremed is ready to proceed with a 12-week Phase 2b study in patients with moderate to severe PDPN in the US. The newly acquired candidate MP-101, a Phase 2 clinical candidate, is an orally available modulator of glutamate signaling. It works by preventing or reversing the ramped-up signaling that occurs in the spine and brain due to damaged peripheral nerves. MP-101 is a patented non-racemic mixture of dimiracetam enantiomers with patent protection until 2039. Based on positive results from Phase 1 and Phase 2 clinical studies, MP-101 is being developed to manage chemotherapy-induced neuropathy and neuropathic pain. The Phase 2 trial is expected to start in the first quarter of 2023. Another candidate, MP-103, a glutamate signaling modulator orally active in diverse rodent models for preventing and treating peripheral nerve injury symptoms, is set to start Phase 1 clinical development in the first half of 2023.

Metys Pharmaceuticals Frequently Asked Questions (FAQ)

  • When was Metys Pharmaceuticals founded?

    Metys Pharmaceuticals was founded in 2013.

  • Where is Metys Pharmaceuticals's headquarters?

    Metys Pharmaceuticals's headquarters is located at Gerbergasse 30, Basel.

  • What is Metys Pharmaceuticals's latest funding round?

    Metys Pharmaceuticals's latest funding round is Acquired.

  • How much did Metys Pharmaceuticals raise?

    Metys Pharmaceuticals raised a total of $60K.

  • Who are the investors of Metys Pharmaceuticals?

    Investors of Metys Pharmaceuticals include Novaremed and EIC Accelerator .

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.